Epizyme (EPZM) Raised to Hold at BidaskClub
Epizyme (NASDAQ:EPZM) was upgraded by stock analysts at BidaskClub from a “sell” rating to a “hold” rating in a research note issued on Saturday.
A number of other brokerages have also recently issued reports on EPZM. Royal Bank of Canada reissued a “buy” rating and issued a $20.00 target price on shares of Epizyme in a research report on Friday, September 15th. Cann reissued a “buy” rating and issued a $26.00 target price on shares of Epizyme in a research report on Tuesday, December 12th. HC Wainwright reissued a “buy” rating and issued a $25.00 target price on shares of Epizyme in a research report on Thursday, November 2nd. Oppenheimer reissued a “buy” rating and issued a $26.00 target price on shares of Epizyme in a research report on Tuesday, September 19th. Finally, Zacks Investment Research raised Epizyme from a “hold” rating to a “buy” rating and set a $20.00 target price for the company in a research report on Monday, October 16th. Two research analysts have rated the stock with a sell rating, two have issued a hold rating and nine have issued a buy rating to the stock. The company currently has a consensus rating of “Buy” and an average target price of $22.67.
Epizyme (NASDAQ:EPZM) traded up $1.20 during trading hours on Friday, hitting $14.40. The stock had a trading volume of 760,151 shares, compared to its average volume of 475,712. The firm has a market cap of $1,090.00, a PE ratio of -6.34 and a beta of 2.00. Epizyme has a twelve month low of $9.30 and a twelve month high of $20.45.
Epizyme (NASDAQ:EPZM) last released its quarterly earnings data on Wednesday, November 1st. The biopharmaceutical company reported ($0.63) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.65) by $0.02. research analysts expect that Epizyme will post -2.23 earnings per share for the current fiscal year.
In other news, insider Peter Tai-Ching Ho sold 15,000 shares of the stock in a transaction that occurred on Tuesday, October 24th. The stock was sold at an average price of $16.44, for a total transaction of $246,600.00. Following the completion of the transaction, the insider now directly owns 23,123 shares of the company’s stock, valued at approximately $380,142.12. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Corporate insiders own 25.20% of the company’s stock.
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in EPZM. Rhumbline Advisers increased its stake in Epizyme by 2.6% in the 2nd quarter. Rhumbline Advisers now owns 50,140 shares of the biopharmaceutical company’s stock valued at $757,000 after purchasing an additional 1,257 shares in the last quarter. State of Wisconsin Investment Board acquired a new stake in Epizyme during the 2nd quarter valued at $408,000. SG Americas Securities LLC grew its holdings in Epizyme by 83.3% during the 2nd quarter. SG Americas Securities LLC now owns 13,364 shares of the biopharmaceutical company’s stock valued at $202,000 after buying an additional 6,072 shares during the last quarter. BB&T Securities LLC acquired a new stake in Epizyme during the 2nd quarter valued at $181,000. Finally, Federated Investors Inc. PA grew its holdings in Epizyme by 477.6% during the 2nd quarter. Federated Investors Inc. PA now owns 89,505 shares of the biopharmaceutical company’s stock valued at $1,352,000 after buying an additional 74,009 shares during the last quarter. 85.28% of the stock is owned by hedge funds and other institutional investors.
TRADEMARK VIOLATION NOTICE: “Epizyme (EPZM) Raised to Hold at BidaskClub” was published by Watch List News and is the property of of Watch List News. If you are accessing this piece on another website, it was copied illegally and reposted in violation of U.S. and international trademark and copyright legislation. The original version of this piece can be viewed at https://www.watchlistnews.com/epizyme-epzm-raised-to-hold-at-bidaskclub/1797629.html.
Epizyme, Inc is a clinical-stage biopharmaceutical company. The Company discovers, develops and plans to commercialize epigenetic therapies for cancer patients. The Company is engaged in the discovery and development of novel epigenetic therapies for cancer patients. The Company develops small molecule inhibitors of a class of enzymes known as histone methyltransferases (HMTs).
Receive News & Ratings for Epizyme Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Epizyme and related companies with Analyst Ratings Network's FREE daily email newsletter.